On Air Now

Current Show

Coast to Coast AM   12:00 AM - 5:00 AM

Contact Coast to Coast AM at 1-800-825-5033

Show Info »

Upcoming Shows

Program Schedule »

Listen

Listen Live Now » 550 AM Wausau, WI 99.9 FM Stevens Point, WI

Weather

Current Conditions(Wausau,WI 54403)

More Weather »
61° Feels Like: 61°
Wind: W 0 mph Past 24 hrs - Precip: 0.04”
Current Radar for Zip

Tonight

Clear 56°

Tomorrow

Scattered Thunderstorms 79°

Sat Night

Mostly Clear 55°

Alerts

Transition Therapeutics' Alzheimer's drug gets FDA fast-track status

(Reuters) - Canadian biopharmaceutical company Transition Therapeutics said the U.S. Food and Drug Administration granted a fast-track status to its Alzheimer's drug, sending its U.S.-listed shares up 33 percent in post-market trading.

A fast track designation by the FDA expedites regulatory review of drugs that aim to treat serious diseases and fill unmet medical needs.

The drug, ELND005, currently being tested in a mid-stage trial, treats neuropsychiatric symptoms such as agitation or aggression in Alzheimer's disease.

Transition Therapeutics said the drug appeared to decrease the emergence and severity of specific neuropsychiatric symptoms in a previous mid-stage study.

About 90 percent of Alzheimer's patients develop neuropsychiatric symptoms and up to 60 percent develop agitation over the course of their disease, the company said.

Ireland-based Elan Corp Plc is Transition's marketing and development partner.

Transition Therapeutics' Toronto-listed shares closed at C$3.15 on Wednesday.

(Reporting by Krithika Krishnamurthy in Bangalore; Editing by Sriraj Kalluvila)

Comments